IPO Year: 2019
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | $74.00 | Overweight | Cantor Fitzgerald |
| 4/16/2025 | $25.00 | Buy | Chardan Capital Markets |
| 1/10/2025 | $155.00 | Outperform | Oppenheimer |
| 10/21/2024 | $153.00 | Strong Buy | Raymond James |
| 8/14/2024 | $180.00 | Outperform | William Blair |
| 3/28/2024 | $100.00 → $115.00 | Buy | H.C. Wainwright |
| 2/27/2024 | $120.00 | Outperform | BMO Capital Markets |
| 12/4/2023 | $100.00 | Buy | H.C. Wainwright |
| 11/29/2023 | $70.00 | Outperform | RBC Capital Mkts |
| 11/10/2023 | $180.00 | Overweight | Piper Sandler |
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference Dr. Aiyar and Dr. Olugemo, will present on Monday, June 9, 2025, at 4:00 p.m. ET. A live webc
—Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027 —Second development candidate expected to be announced in 2025 —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketable securities CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of gene
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i
—Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 —U.S. Food and Drug Administration (FDA) Granted Orphan Drug Designation to KRRO-110 for the treatment of AATD —Executing 3-2-1 strategy through end of 2027 with the goal of establishing three clinical-stage development programs, targeting two tissue types with a single RNA-editing platform; Second development candidate expected to be announced in 2025 —Strengthened leadership team with the formation of Clinical Advisory Board and key additions to board and management team —Ended 2024 with a strong balance
CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). "Receiving orphan drug designation from the FDA underscores the growing need for new treatments for patients living with AATD," said Kemi Olugemo, MD, Chief Medical Officer at Korro. "KRRO-110 has the potential to treat both liver and lung
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m. ET at the Boston Marriott Copley Place. Todd Chappell, Chief Operating Officer, will also participate in 1x1 investor meetings at the conference. A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section
KRRO-110 is the first product candidate from Korro's proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to advance additional pipeline programs towards clinical development CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced the initiation of dosing in its REWRITE study investigating KRRO-110 as a potential treatment for individuals with Alpha-1 Antitrypsin Deficiency (AATD). "KRRO-110 is designed to restore thera
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the Westin St. Francis in San Francisco. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on t
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, December 3, 2024, at 4:00 p.m. ET. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in 1x1 investor meetings at the conferenc
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
Cantor Fitzgerald initiated coverage of Korro Bio with a rating of Overweight and set a new price target of $74.00
Chardan Capital Markets initiated coverage of Korro Bio with a rating of Buy and set a new price target of $25.00
Oppenheimer initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $155.00
Raymond James initiated coverage of Korro Bio with a rating of Strong Buy and set a new price target of $153.00
William Blair initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $180.00
H.C. Wainwright reiterated coverage of Korro Bio with a rating of Buy and set a new price target of $115.00 from $100.00 previously
BMO Capital Markets initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $120.00
H.C. Wainwright initiated coverage of Korro Bio with a rating of Buy and set a new price target of $100.00
RBC Capital Mkts initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $70.00
Piper Sandler initiated coverage of Korro Bio with a rating of Overweight and set a new price target of $180.00
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i
CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th
- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024 Further strengthened balance sheet with closing of $70.0 million private placement (PIPE) on April 22, 2024, with cash and cash equivalents of approximately $206 million at close Cash runway into second half of 2026 to fund anticipated interim readout of KRRO-110 in the second half of 2025 and FIH study completion in 2026 Appointed Kemi Olugemo, M.D., FANN as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company
Biotech veteran brings more than two decades of life science experience to Korro's Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform, today announced the appointment of Rachel Meyers, PhD, to the Company's Board of Directors. "Rachel is one of the pioneers in advancing LNP and conjugate-based oligonucleotide therapies to the clinic and generating regulatory approvals," said Ram Aiyar, PhD, Chief Executive Officer of Korro. "With over two decades of research, development and
10-Q - Korro Bio, Inc. (0001703647) (Filer)
8-K - Korro Bio, Inc. (0001703647) (Filer)
DEFA14A - Korro Bio, Inc. (0001703647) (Filer)
DEF 14A - Korro Bio, Inc. (0001703647) (Filer)
8-K - Korro Bio, Inc. (0001703647) (Filer)
S-8 - Korro Bio, Inc. (0001703647) (Filer)
10-K - Korro Bio, Inc. (0001703647) (Filer)
8-K - Korro Bio, Inc. (0001703647) (Filer)
SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SCHEDULE 13G - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G - Korro Bio, Inc. (0001703647) (Subject)
SC 13D/A - Korro Bio, Inc. (0001703647) (Subject)